BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

DBV Technologies 

29 rue du Faubourg

Saint Jacques  Paris  75014  France
Phone: 33-0-1-55-389270 Fax: 33-0-1-41-312882


SEARCH JOBS










 Company News
DBV Technologies Completes Last "Food Challenge" Visit Of Last Peanut-Allergic Patient In VIPES Phase 2b Clinical Study 7/17/2014 10:15:00 AM
Consortium Of Food Allergy Research Completes Recruitment Of National Institutes of Health (NIH)-Sponsored Cofar6 Phase 2Trial With DBV Technologies's Viaskin® Peanut In Treatment Of Peanut Allergy 7/17/2014 6:12:23 AM
DBV Technologies To Present At Upcoming US Investors Conferences 6/17/2014 9:13:11 AM
Five Scientific Communications At The European Academy Of Allergy And Clinical Immunology Congress Further Support DBV Technologies's EPIT™ Disease Modifying Effect 6/11/2014 7:18:56 AM
DBV Technologies Announces Clinical Trial Agreement To Develop A Treatment For Milk-Induced Eosinophilic Esophagitis In Children 5/13/2014 11:54:21 AM
DBV Technologies To Host And Webcast Investor Day In New York City On May 21, 2014 5/12/2014 10:05:48 AM
DBV Technologies Announces The First Reported Case Of A Long Term Sustained Effect Of Peanut Desensitization After Epicutaneous Immunotherapy (EPIT) With Viaskin® At The French Congress Of Allergy 4/16/2014 9:51:14 AM
DBV Technologies Announces Topline Financial Results For First Three Months 2014 4/15/2014 9:37:37 AM
DBV Technologies And CEA Conclude A Scientific Cooperation To Investigate Epigenetic Modulation In Epicutaneous Immunotherapy 4/9/2014 8:49:18 AM
DBV Technologies Announces Creation Of US Subsidiary And Appoints Ms. Susanna Mesa As Vice President Of Finance, U.S. Investor Relations & Strategy 4/7/2014 9:13:53 AM
123456